PBG BioPharma® Inc.’s Post

How do you wake up Advisory BORED meetings? The difference is in the details. See how our KOL Connection Services bring your BioPharma ad boards to life: https://lnkd.in/gWemd3Xm #adboard #kols #biopharma

Join the next Pharmaversity session with Diana Löber!

It is an incredible honor to be part of this Entrepreneurial Advisory Board by Peptide Drug Hunting Consortium. This is why I joined... 💙Peptides became my scientific passion after I started Belyntic GmbH with Robert Zitterbart, Andreas Regnery, and Oliver Reimann. Initially, coming from more (bio)analytical materials design (check out SAFIA Technologies), I helped to develop PEC technology as a new way to purify and modify peptides. After some time, I focused on communications to help translate our solution for customers and stakeholders.  🚀My time as a founder allowed me to dive into the #peptide community. I met so many fascinating and inspiring scientists, entrepreneurs, and corporate executives, and it was a pleasure to see how they were all pulling together for a shared dream of better lives with the power of peptides. 🎯Ultimately, I found my place in a senior marketing role at Gyros Protein Technologies, where I could widen my scope to the whole manufacturing workflow, including automated synthesis. My fascination for peptide science, particularly synthesis and purification, still drives me, knowing that this is a crucial challenge to developing and manufacturing novel and powerful peptide drugs: 🔮The way to the #bestpossibledrug is not a miracle—it is a question of translating a target-driven molecular design into an actionable result through the synthesis and purification of a peptide or peptide library that is most likely modified, conjugated, or structurally altered in any other form. 🌳Improving the ecological impact of synthesis and purification is probably the most significant challenge in making peptide-based drugs. That is true for the multi-ton manufacture of GLP-1 analogs and many other NCEs that will enter the market. 💰In the end, a drug has the most impact if it helps people worldwide, regardless of their monetary status. Therefore, cutting down the cost of peptide manufacturing is an essential landmark for the future success of this drug class. 💡My aim at the PDHC is to help overcome synthesis and purification challenges in peptide drug development through innovation. I hope to add value with my experience and expertise in that field to enable the best possible, sustainable, and affordable peptide drugs to improve life and health for everyone. Please take a minute and check out and follow the LinkedIn page of the PDHC: https://lnkd.in/ee7R3MED Thanks, team #Peptidedrughunting, for allowing me to participate in this initiative. I am looking forward to working with you all.

Quick tricks to improve patient care!

As the population of the US continues to diversify, creating an inclusive healthcare environment will become even more crucial. Join Dr Taylor and myself as we review some practical tips that you can incorporate into your everyday clinical practice to ensure each person feels welcome and recognized for their own unique selves! #diversity #inclusivity #breakingbarriers

Taking an Intro to Biotech Course at IVC to learn more about the fundamentals for the industry I work in. Incredible to see the stats on the success rate of the compounds evaluated throughout the FDA clinical Phases. (Source: "Intro to Biotech," Thieman & Palladino)

This means recruitment of patients for Lipisense Phase II can start.

GLP-1R Agonist Peptides are driving up revenues at Both Novo and Lilly, both of which could become the first and second Trillion $ market cap pharmas. Zealand is a longterm player in this field having been a competitor of Novo as far back as the early millennium. Considering product shortages there is room for additional players in this space. https://lnkd.in/eZDdQFYD

FDA approves first two interchangeable biosimilars to Regeneron's blockbuster Eylea Eylea will eventually have competition in the US, as the FDA approved two interchangeable biosimilars. Monday’s approvals for Biocon Biologics’ Yesafili and Samsung Bioepis and Biogen’s Opuviz are based on the companies’ ability to show that their aflibercept competitors have no clinically meaningful differences from brand-name Eylea. Yesafili won approval in the UK last November and in Europe last September. “This evidence included comparisons of each product to Eylea on an analytical level using an extensive and robust battery of physicochemical tests and biological assays, and in a comparative clinical study in patients,” FDA said in announcing the approvals. Sandoz also has another Eylea biosimilar in the works. While most interchangeable biosimilars have to run switching studies to win approval, FDA confirmed to Endpoints that neither interchangeable for Eylea had to run such studies. The agency said “the risk of a clinically impactful immunogenic response when alternating or switching between Yesafili and Eylea or Opuviz and Eylea is low. Thus, a switching study that compares immunogenic responses to assess whether the risk of alternating or switching between Yesafili and Eylea or Opuviz and Eylea were unnecessary for either product.” But because of remaining patents on Eylea, analysts don’t expect either of the two new biosimilars to launch until 2027. In August, Regeneron also launched a high-dose version of Eylea that it hopes will become the standard of care in several retinal diseases. In its first-quarter filing, Regeneron recorded $200 million in US sales of the high-dose version, and about $2.3 billion in worldwide sales of Eylea and Eylea HD. Competition from interchangeable biosimilars is increasing for some of the biggest drugs in the world, including AbbVie’s Humira. Regeneron reported more than $12 billion in Eylea sales in 2022 and 2023. Eylea may also be up for Medicare negotiations in the next few years — in 2022, Medicare Part B spent more money on Eylea than any other drug except Merck’s Keytruda. https://lnkd.in/eSRuCBTs

Shield Therapeutics plc (AIM:STX, OTCQX:SHIEF) interim CEO Anders Lundstrom and CFO Santosh Shanbhag take Proactive's Stephen Gunnion through the company's impressive growth in the iron deficiency market. They discussed the key highlights from the first half of the year, including a 3.5x increase in Accrufer revenues, bringing in $11 million in total net revenue. Shanbhag emphasised this growth was driven by both increased prescriptions and improved pricing strategies. Lundstrom provided insights into Shield Therapeutics' broader market strategy, focusing on their collaboration with Viatris and global partners to expand Accrufer's reach. He highlighted recent milestones such as Health Canada's approval of Accrufer, marking a significant step in the company's global expansion. Shanbhag further detailed Shield's financial positioning, including maintaining $8.1 million in cash and strategic financing moves to support... Watch at #Proactive #ProactiveInvestors http://ow.ly/Re8U105HBFB